Bio-Techne (TECH) Stake Raised by Teachers Advisors LLC

Teachers Advisors LLC grew its position in Bio-Techne (NASDAQ:TECH) by 15.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,189 shares of the biotechnology company’s stock after acquiring an additional 6,407 shares during the quarter. Teachers Advisors LLC owned about 0.13% of Bio-Techne worth $6,243,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Amalgamated Bank raised its stake in shares of Bio-Techne by 5.4% in the fourth quarter. Amalgamated Bank now owns 7,772 shares of the biotechnology company’s stock valued at $1,007,000 after acquiring an additional 399 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Bio-Techne by 3.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 12,180 shares of the biotechnology company’s stock valued at $1,473,000 after acquiring an additional 452 shares during the period. Advisor Group Inc. raised its stake in shares of Bio-Techne by 64.5% in the fourth quarter. Advisor Group Inc. now owns 1,288 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 505 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Bio-Techne by 42.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,069 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 613 shares during the period. Finally, Confluence Investment Management LLC raised its stake in shares of Bio-Techne by 2.3% in the fourth quarter. Confluence Investment Management LLC now owns 31,875 shares of the biotechnology company’s stock valued at $4,130,000 after acquiring an additional 727 shares during the period. 97.12% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

NASDAQ TECH opened at $145.33 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.49 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $5,554.02, a PE ratio of 42.49, a P/E/G ratio of 2.84 and a beta of 0.70. Bio-Techne has a 12 month low of $98.35 and a 12 month high of $151.89.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.10. The firm had revenue of $154.15 million for the quarter, compared to analysts’ expectations of $145.93 million. Bio-Techne had a net margin of 19.17% and a return on equity of 14.39%. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 earnings per share. equities research analysts anticipate that Bio-Techne will post 4.01 earnings per share for the current year.

In other news, Director Charles A. Dinarello sold 5,000 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total value of $680,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.40% of the company’s stock.

A number of research firms have recently commented on TECH. BidaskClub upgraded shares of Bio-Techne from a “buy” rating to a “strong-buy” rating in a report on Friday, March 16th. ValuEngine upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Deutsche Bank set a $163.00 price target on shares of Bio-Techne and gave the stock a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a report on Saturday, January 20th. Finally, Robert W. Baird restated a “buy” rating and issued a $154.00 price target on shares of Bio-Techne in a report on Thursday, January 18th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Bio-Techne presently has a consensus rating of “Buy” and a consensus price target of $148.60.

COPYRIGHT VIOLATION WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3340735/bio-techne-tech-stake-raised-by-teachers-advisors-llc.html.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne (NASDAQ:TECH).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Stanley Black & Decker  Posts Quarterly  Earnings Results, Beats Estimates By $0.04 EPS
Stanley Black & Decker Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Sling Trading Down 40.5% Over Last 7 Days
Sling Trading Down 40.5% Over Last 7 Days
Nuls Price Reaches $2.64 on Exchanges
Nuls Price Reaches $2.64 on Exchanges
TriplePoint Venture Growth BDC  Receives Daily Media Impact Rating of 0.12
TriplePoint Venture Growth BDC Receives Daily Media Impact Rating of 0.12
Kforce  Stock Rating Upgraded by BidaskClub
Kforce Stock Rating Upgraded by BidaskClub
Blackhawk Network  Downgraded by BidaskClub
Blackhawk Network Downgraded by BidaskClub


Leave a Reply

© 2006-2018 Ticker Report. Google+.